Amdocs (DOX) Competitors

$62.97 +0.61 (+0.98%)

As of 01:51 PM Eastern

DOX vs. CTSH, LDOS, CACI, IT, and BAH

Should you buy Amdocs stock or one of its competitors? MarketBeat compares Amdocs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amdocs include Cognizant Technology Solutions (CTSH), Leidos (LDOS), CACI International (CACI), Gartner (IT), and Booz Allen Hamilton (BAH). These companies are all part of the "it consulting & other services" industry.

How does Amdocs compare to Cognizant Technology Solutions?

Amdocs (NASDAQ:DOX) and Cognizant Technology Solutions (NASDAQ:CTSH) are both computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Amdocs has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Cognizant Technology Solutions has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Amdocs has a net margin of 11.81% compared to Cognizant Technology Solutions' net margin of 10.41%. Amdocs' return on equity of 19.77% beat Cognizant Technology Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amdocs	11.81%	19.77%	10.87%
Cognizant Technology Solutions	10.41%	17.50%	12.94%

Cognizant Technology Solutions has higher revenue and earnings than Amdocs. Cognizant Technology Solutions is trading at a lower price-to-earnings ratio than Amdocs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amdocs	$4.62B	1.48	$564.70M	$5.00	12.65
Cognizant Technology Solutions	$21.11B	1.19	$2.23B	$4.60	11.49

Amdocs currently has a consensus price target of $86.67, indicating a potential upside of 36.99%. Cognizant Technology Solutions has a consensus price target of $73.00, indicating a potential upside of 38.15%. Given Cognizant Technology Solutions' stronger consensus rating and higher probable upside, analysts clearly believe Cognizant Technology Solutions is more favorable than Amdocs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amdocs	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cognizant Technology Solutions	0 Sell rating(s)	12 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.45

92.0% of Amdocs shares are owned by institutional investors. Comparatively, 92.4% of Cognizant Technology Solutions shares are owned by institutional investors. 15.4% of Amdocs shares are owned by insiders. Comparatively, 0.4% of Cognizant Technology Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amdocs pays an annual dividend of $2.27 per share and has a dividend yield of 3.6%. Cognizant Technology Solutions pays an annual dividend of $1.32 per share and has a dividend yield of 2.5%. Amdocs pays out 45.4% of its earnings in the form of a dividend. Cognizant Technology Solutions pays out 28.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amdocs has raised its dividend for 14 consecutive years and Cognizant Technology Solutions has raised its dividend for 6 consecutive years. Amdocs is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Cognizant Technology Solutions had 14 more articles in the media than Amdocs. MarketBeat recorded 19 mentions for Cognizant Technology Solutions and 5 mentions for Amdocs. Cognizant Technology Solutions' average media sentiment score of 1.13 beat Amdocs' score of 0.66 indicating that Cognizant Technology Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amdocs	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognizant Technology Solutions	12 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cognizant Technology Solutions beats Amdocs on 11 of the 19 factors compared between the two stocks.

How does Amdocs compare to Leidos?

Leidos (NYSE:LDOS) and Amdocs (NASDAQ:DOX) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Leidos had 5 more articles in the media than Amdocs. MarketBeat recorded 10 mentions for Leidos and 5 mentions for Amdocs. Amdocs' average media sentiment score of 0.66 beat Leidos' score of 0.13 indicating that Amdocs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Leidos	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Amdocs	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amdocs has a net margin of 11.81% compared to Leidos' net margin of 8.15%. Leidos' return on equity of 31.92% beat Amdocs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Leidos	8.15%	31.92%	11.23%
Amdocs	11.81%	19.77%	10.87%

Leidos currently has a consensus target price of $193.64, indicating a potential upside of 54.13%. Amdocs has a consensus target price of $86.67, indicating a potential upside of 36.99%. Given Leidos' stronger consensus rating and higher probable upside, equities analysts plainly believe Leidos is more favorable than Amdocs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Leidos	0 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.62
Amdocs	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Leidos pays an annual dividend of $1.72 per share and has a dividend yield of 1.4%. Amdocs pays an annual dividend of $2.27 per share and has a dividend yield of 3.6%. Leidos pays out 15.8% of its earnings in the form of a dividend. Amdocs pays out 45.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Leidos has raised its dividend for 6 consecutive years and Amdocs has raised its dividend for 14 consecutive years. Amdocs is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Leidos has higher revenue and earnings than Amdocs. Leidos is trading at a lower price-to-earnings ratio than Amdocs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Leidos	$17.33B	0.91	$1.45B	$10.92	11.50
Amdocs	$4.62B	1.48	$564.70M	$5.00	12.65

76.1% of Leidos shares are owned by institutional investors. Comparatively, 92.0% of Amdocs shares are owned by institutional investors. 0.8% of Leidos shares are owned by insiders. Comparatively, 15.4% of Amdocs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Leidos has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Amdocs has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Summary

Leidos beats Amdocs on 12 of the 20 factors compared between the two stocks.

How does Amdocs compare to CACI International?

Amdocs (NASDAQ:DOX) and CACI International (NYSE:CACI) are both computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

92.0% of Amdocs shares are held by institutional investors. Comparatively, 86.4% of CACI International shares are held by institutional investors. 15.4% of Amdocs shares are held by insiders. Comparatively, 1.1% of CACI International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, CACI International had 3 more articles in the media than Amdocs. MarketBeat recorded 8 mentions for CACI International and 5 mentions for Amdocs. Amdocs' average media sentiment score of 0.66 beat CACI International's score of 0.26 indicating that Amdocs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amdocs	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CACI International	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amdocs has higher earnings, but lower revenue than CACI International. Amdocs is trading at a lower price-to-earnings ratio than CACI International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amdocs	$4.62B	1.48	$564.70M	$5.00	12.65
CACI International	$8.63B	1.27	$499.83M	$24.24	20.51

Amdocs has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, CACI International has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Amdocs presently has a consensus target price of $86.67, suggesting a potential upside of 36.99%. CACI International has a consensus target price of $635.60, suggesting a potential upside of 27.83%. Given Amdocs' higher possible upside, research analysts clearly believe Amdocs is more favorable than CACI International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amdocs	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
CACI International	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.77

Amdocs has a net margin of 11.81% compared to CACI International's net margin of 5.86%. Amdocs' return on equity of 19.77% beat CACI International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amdocs	11.81%	19.77%	10.87%
CACI International	5.86%	15.90%	6.86%

Summary

Amdocs beats CACI International on 9 of the 17 factors compared between the two stocks.

How does Amdocs compare to Gartner?

Gartner (NYSE:IT) and Amdocs (NASDAQ:DOX) are both it consulting & other services companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

91.5% of Gartner shares are held by institutional investors. Comparatively, 92.0% of Amdocs shares are held by institutional investors. 2.6% of Gartner shares are held by company insiders. Comparatively, 15.4% of Amdocs shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Gartner presently has a consensus price target of $176.70, suggesting a potential upside of 10.03%. Amdocs has a consensus price target of $86.67, suggesting a potential upside of 36.99%. Given Amdocs' stronger consensus rating and higher probable upside, analysts clearly believe Amdocs is more favorable than Gartner.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gartner	2 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amdocs	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Gartner had 10 more articles in the media than Amdocs. MarketBeat recorded 15 mentions for Gartner and 5 mentions for Amdocs. Amdocs' average media sentiment score of 0.66 beat Gartner's score of 0.26 indicating that Amdocs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gartner	2 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Amdocs	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Gartner has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Amdocs has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Gartner has higher revenue and earnings than Amdocs. Amdocs is trading at a lower price-to-earnings ratio than Gartner, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gartner	$6.47B	1.66	$729.23M	$10.12	15.87
Amdocs	$4.62B	1.48	$564.70M	$5.00	12.65

Amdocs has a net margin of 11.81% compared to Gartner's net margin of 11.44%. Gartner's return on equity of 161.39% beat Amdocs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gartner	11.44%	161.39%	12.74%
Amdocs	11.81%	19.77%	10.87%

Summary

Gartner beats Amdocs on 9 of the 16 factors compared between the two stocks.

How does Amdocs compare to Booz Allen Hamilton?

Amdocs (NASDAQ:DOX) and Booz Allen Hamilton (NYSE:BAH) are both mid-cap it consulting & other services companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Amdocs has a net margin of 11.81% compared to Booz Allen Hamilton's net margin of 7.35%. Booz Allen Hamilton's return on equity of 76.79% beat Amdocs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amdocs	11.81%	19.77%	10.87%
Booz Allen Hamilton	7.35%	76.79%	10.95%

Amdocs currently has a consensus price target of $86.67, indicating a potential upside of 36.99%. Booz Allen Hamilton has a consensus price target of $93.33, indicating a potential upside of 19.01%. Given Amdocs' stronger consensus rating and higher possible upside, equities research analysts plainly believe Amdocs is more favorable than Booz Allen Hamilton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amdocs	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Booz Allen Hamilton	4 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Booz Allen Hamilton has higher revenue and earnings than Amdocs. Booz Allen Hamilton is trading at a lower price-to-earnings ratio than Amdocs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amdocs	$4.62B	1.48	$564.70M	$5.00	12.65
Booz Allen Hamilton	$11.98B	0.79	$935M	$6.73	11.65

92.0% of Amdocs shares are owned by institutional investors. Comparatively, 91.8% of Booz Allen Hamilton shares are owned by institutional investors. 15.4% of Amdocs shares are owned by company insiders. Comparatively, 0.9% of Booz Allen Hamilton shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Amdocs has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Booz Allen Hamilton has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

In the previous week, Booz Allen Hamilton had 10 more articles in the media than Amdocs. MarketBeat recorded 15 mentions for Booz Allen Hamilton and 5 mentions for Amdocs. Amdocs' average media sentiment score of 0.66 beat Booz Allen Hamilton's score of 0.38 indicating that Amdocs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amdocs	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Booz Allen Hamilton	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amdocs pays an annual dividend of $2.27 per share and has a dividend yield of 3.6%. Booz Allen Hamilton pays an annual dividend of $2.36 per share and has a dividend yield of 3.0%. Amdocs pays out 45.4% of its earnings in the form of a dividend. Booz Allen Hamilton pays out 35.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amdocs has increased its dividend for 14 consecutive years and Booz Allen Hamilton has increased its dividend for 14 consecutive years.

Summary

Amdocs beats Booz Allen Hamilton on 11 of the 18 factors compared between the two stocks.

Get Amdocs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DOX vs. The Competition

Export

Metric	Amdocs	IT Services Industry	Computer Sector	NASDAQ Exchange
Market Cap	$6.82B	$13.09B	$39.18B	$12.34B
Dividend Yield	3.67%	2.44%	3.21%	5.33%
P/E Ratio	12.64	49.20	78.89	25.65
Price / Sales	1.48	9.22	629.54	85.61
Price / Cash	7.99	24.95	46.90	56.16
Price / Book	2.00	3.62	10.55	7.06
Net Income	$564.70M	$537.84M	$1.06B	$335.04M
7 Day Performance	4.44%	3.65%	2.94%	2.60%
1 Month Performance	-3.75%	-5.79%	5.73%	1.42%
1 Year Performance	-30.95%	-14.39%	167.64%	35.67%

Amdocs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DOX Amdocs	4.5547 of 5 stars	$62.97 +1.0%	$86.67 +37.6%	-32.0%	$6.80B	$4.62B	12.59	26,969
CTSH Cognizant Technology Solutions	4.7978 of 5 stars	$46.05 +0.2%	$73.33 +59.2%	-34.6%	$21.82B	$21.11B	10.01	351,600	Positive News Buyback Announcement
LDOS Leidos	4.8574 of 5 stars	$125.55 +1.1%	$193.64 +54.2%	-22.7%	$15.79B	$17.17B	11.50	47,000
CACI CACI International	4.2878 of 5 stars	$505.62 +0.3%	$641.50 +26.9%	+3.6%	$11.17B	$9.16B	20.86	25,000	Positive News Analyst Downgrade
IT Gartner	3.8518 of 5 stars	$140.88 -2.5%	$176.70 +25.4%	-64.5%	$9.93B	$6.50B	13.92	20,244

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DOX) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amdocs (DOX) Competitors

DOX vs. CTSH, LDOS, CACI, IT, and BAH

How does Amdocs compare to Cognizant Technology Solutions?

Summary

How does Amdocs compare to Leidos?

Summary

How does Amdocs compare to CACI International?

Summary

How does Amdocs compare to Gartner?

Summary

How does Amdocs compare to Booz Allen Hamilton?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOX vs. The Competition

Amdocs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amdocs (DOX) Competitors

DOX vs. CTSH, LDOS, CACI, IT, and BAH

How does Amdocs compare to Cognizant Technology Solutions?

Which has more volatility and risk, DOX or CTSH?

Is DOX or CTSH more profitable?

Which has better valuation & earnings, DOX or CTSH?

Do analysts rate DOX or CTSH?

Do insiders & institutionals have more ownership in DOX or CTSH?

Is DOX or CTSH a better dividend stock?

Does the media refer more to DOX or CTSH?

Summary

How does Amdocs compare to Leidos?

Does the media refer more to LDOS or DOX?

Is LDOS or DOX more profitable?

Do analysts rate LDOS or DOX?

Is LDOS or DOX a better dividend stock?

Which has better earnings and valuation, LDOS or DOX?

Do insiders and institutionals believe in LDOS or DOX?

Which has more volatility & risk, LDOS or DOX?

Summary

How does Amdocs compare to CACI International?

Do insiders & institutionals hold more shares of DOX or CACI?

Does the media favor DOX or CACI?

Which has stronger earnings and valuation, DOX or CACI?

Which has more volatility & risk, DOX or CACI?

Do analysts prefer DOX or CACI?

Is DOX or CACI more profitable?

Summary

How does Amdocs compare to Gartner?

Do insiders and institutionals believe in IT or DOX?

Do analysts prefer IT or DOX?

Does the media prefer IT or DOX?

Which has more risk and volatility, IT or DOX?

Which has preferable earnings & valuation, IT or DOX?

Is IT or DOX more profitable?

Summary

How does Amdocs compare to Booz Allen Hamilton?

Is DOX or BAH more profitable?

Do analysts rate DOX or BAH?

Which has preferable earnings and valuation, DOX or BAH?

Do institutionals & insiders hold more shares of DOX or BAH?

Which has more risk & volatility, DOX or BAH?

Does the media prefer DOX or BAH?

Is DOX or BAH a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOX vs. The Competition

Amdocs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools